Group 1 - The company RenDu Bio announced that its second board meeting of the 15th session will be held on January 15, 2026, to review the proposal regarding expected daily related transactions for the year 2026 [1] Group 2 - The silver market has seen a significant increase, with prices rising over 80% in the last 50 days, indicating a potential peak in the precious metals bull market [1]

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 募投项目延期的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）的保荐机构，根据《证 券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创 板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关法律、行政法规、部门规章及业务规则的要求，对仁度生物募投项目延期的 事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2022]332 号文），并经上海证券交易所同意，公 司于 2022 年 3 月向社会公开发行人民币普通股 10,000,000 股，每股面值人民币 1.00 元， 溢价发行，每股发行价为人民币 72.65 元，募集资金总额为人民币 726,500,000.00 元， 扣除不含税的发行费用人民币 73,735,099.95 元，公司实际募集 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 预计 2026 年度日常关联交易的核查意见 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司第二届董事会独立董事专门会议第五次会议审议通过了《关于公司预计 2026 年度日常关联交易的议案》，独立董事认为：公司预计的 2026 年度日常关联交易符合 公司的经营发展需要，关联交易遵循了公平、合理的原则，该类关联交易对公司独立性 无重大不利影响，不会对公司及公司财务状况、经营成果产生重大不利影响，不存在损 害公司及全体股东特别是中小股东利益的情形。公司全体独立董事同意该事项，并同意 将该事项提交公司董事会审议。 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议审议通过了《关于公司预 计 2026 年度日常关联交易的议案》，表决结果为：赞成 7 票，无反对票，无弃权票。 （二）本次日常关联交易预计金额和类别 单位：万元 | 关联交易 | | 本次预计 | 占同类业 | 本年年初至 | 上年实际 | 占同类业 | 本 次 预 计 金 | | --- | --- | --- | --- | --- | --- | --- | ...

| 投资金额 | 不超过人民币 亿元（含本数） 4 | | --- | --- | | 投资种类 | 投资于安全性高、流动性较好的中低风险理财产品，包括但 | | | 不限于协定存款、七天通知存款、结构性存款大额存单、收 | | | 益凭证、债券投资、货币市场基金投资、委托理财等产品 | | 资金来源 | 自有资金 | 证券代码：688193 证券简称：仁度生物 公告编号：2026-002 上海仁度生物科技股份有限公司 关于公司使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 已履行的审议程序 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议，审议通过了《关 于公司使用闲置自有资金购买理财产品的议案》。上述事项在公司董事会审批权 限范围内，无需提交公司股东会审批。 特别风险提示 尽管公司拟投资的理财产品都经过严格的评估，但该类产品受货币政策等宏 观经济政策的影响较大，公司将根据经济形势以及金融市场的变化适时适量介入， 但不排除该项投资收益受到市场波动 ...

证券代码：688193 证券简称：仁度生物 公告编号：2026-003 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议审议通过了《关于 公司预计 2026 年度日常关联交易的议案》，表决结果为：赞成 7 票，无反对票， 无弃权票。 （二）本次日常关联交易预计金额和类别 上海仁度生物科技股份有限公司 关于公司预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会独立董事 专门会议第五次会议审议通过了《关于公司预计 2026 年度日常关联交易的议案》， 独立董事认为：公司预计的 2026 年度日常关联交易符合公司的经营发展需要， 关联交易遵循了公平、合理的原则，该类关联交易对公司独立性无重大不利影响， 不会对公司及公司财务状况、经营成果产生重大不利影响，不存在损害公司及全 体股东特别是中小股东利益的情形。公司全体独立董事同意该事项，并同意将该 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上 海仁度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行 股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上市公司募集资金监管规则》和《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对仁度生物 拟使用部分暂时闲置募集资金进行现金管理事项进行了审慎的核查，具体核查情况 如下： 一、投资情况概述 （一）投资目的 为提高公司募集资金使用效率，在不影响募集资金投资项目建设正常进行的情 况下，根据募集资金投资项目的投资计划和建设进度，合理利用部分暂时闲置募集 资金进行现金管理，增加公司资金收益，为公司及股东获取更多回报。 （二）投资金额 公司拟使用最高余额不超过人民币 3.9 亿元（含本数）的暂时闲置募集资金进 行现金管理，使用期限自公司董事会审议通过之日起 12 个月有效。上述额度在决 议有效期内，资金可以滚动使用，并于到期后归还至募集资 ...

证券代码：688193 证券简称：仁度生物 公告编号：2026-004 上海仁度生物科技股份有限公司 关于公司募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（简称"公司"）于 2026 年 1 月 15 日召开第 二届董事会第十五次会议，审议通过了《关于公司募投项目延期的议案》，同意 公司对首次公开发行股票募集资金投资项目（以下简称"募投项目"）"精准诊断试 剂和智能设备产业化研发项目"、"营销网络建设项目"达到预定可使用状态的时 间进行延期。具体情况公告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]332号文），并经上海证券交易 所同意，公司于2022年3月向社会公开发行人民币普通股10,000,000股，每股面值 人民币1.00元，溢价发行，每股发行价为人民币72.65元，募集资金总额为人民币 726,500,000.00元，扣除不 ...

上海仁度生物科技股份有限公司 关于公司使用部分暂时闲置募集资金进行现金管理 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、具有合法经营资格且为本金保障型 的金融机构销售的投资产品（包括协定存款、定期存款、通知存款、大额存 单、结构性存款、收益凭证等）。 证券代码：688193 证券简称：仁度生物 公告编号：2026-005 投资金额：最高不超过人民币 3.9 亿元（含本数）。 已履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）于 2026 年 1 月 15 日召 开第二届董事会第十五次会议，审议通过了《关于公司使用部分暂时闲置募集资 金进行现金管理的议案》，保荐机构中国国际金融股份有限公司（以下简称"保 荐机构"）对上述事项出具了明确的核查意见。上述事项在公司董事会审批权限 范围内，无需提交公司股东会审议。 特别风险提示 尽管公司拟投资安全性高、流动性好且为本金保障型的投资产品，总体风险 可控，但该类产品受货币政策等宏观经济政策的影响较大，公司将根据经济形 ...

本议案无需提交股东会审议。 证券代码：688193 证券简称：仁度生物 公告编号：2026-001 上海仁度生物科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会第十五次 会议于 2026 年 1 月 15 日以现场结合通讯的表决方式在公司会议室召开，会议应 到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。公司高级管理人 员列席了董事会会议。本次董事会会议的召集、召开程序符合公司章程和有关法 律、法规的要求。经与会董事审议和表决，会议形成决议如下： 一、审议通过《关于公司使用闲置自有资金购买理财产品的 议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 具体内容详见本公司 2026 年 1 月 17 日于上海证券交易所网站 （www.sse.com.cn）披露的《关于公司使用闲置自有资金购买理财产品的公告》 （公告编号：2026-002）。 二、审议通过《关于公司预计 2026 年度日常关 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]